vinay prasad sarepta - Search News

News

Inside fall of Vinay Prasad at FDA

PharmExec · 2d

Vinay Prasad’s FDA Departure Follows Controversy Over Drug Rejections

The FDA’s top vaccine and gene therapy official resigned amid heightened scrutiny over recent drug approval decisions and safety concerns surrounding gene therapies.

Reuters on MSN · 2d

US FDA's top vaccine official Vinay Prasad leaves agency after 3 months

The U.S. Food and Drug Administration's top vaccine official, Vinay Prasad, has left the agency after just three months as Director of the Center for Biologics Evaluation and Research, a government spokesperson said.

What Vinay Prasad’s ouster means for biotech and the FDA

This week on "The Readout LOUD," STAT's biotech reporters parse what Vinay Prasad's ouster means for biotech and the FDA.

3d

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies.

STAT1dOpinion

Vinay Prasad is my former student and friend. His departure from FDA is a loss for American medicine

It is hard to imagine someone more equipped and more dedicated to vetting treatments than Vinay Prasad,” writes his former ...

3don MSN

FDA’s Prasad Exits Following Political Backlash Over Sarepta

Vinay Prasad, a top regulator at the US Food and Drug Administration, has left the agency after a controversy over his ...

3don MSN

Sarepta, Replimmune, Capricor rise as FDA’s biologics head departs

Replimune (NASDAQ:REPL), and Capricor Therapeutics (NASDAQ:CAPR), which faced regulatory setbacks from the FDA’s biologics ...

3don MSN

Dr Vinay Prasad's FDA exit in less than 3 months linked to Sarepta gene therapy controversy? Check details

Dr. Vinay Prasad, a controversial figure and critic of the FDA, resigned from his high-ranking position at the agency after ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results